MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Crinetics Pharmaceuticals Inc

Închisă

SectorSănătate

31.75 -0.72

Rezumat

Modificarea prețului

24h

Curent

Minim

31.16

Maxim

32.15

Indicatori cheie

By Trading Economics

Venit

-16M

-97M

Vânzări

361K

361K

Marjă de profit

-26,807.202

Angajați

437

EBITDA

-17M

-110M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+114.44% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-369M

2.8B

Deschiderea anterioară

32.47

Închiderea anterioară

31.75

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 iul. 2025, 22:19 UTC

Achiziții, Fuziuni, Preluări

FCC Approves U.S. Cellular Sale to T-Mobile

11 iul. 2025, 17:28 UTC

Principalele dinamici ale pieței

SharpLink Gaming Gains on Ethereum Purchase

11 iul. 2025, 16:57 UTC

Câștiguri

BASF Cuts Outlook on Global Economy Uncertainty

11 iul. 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 iul. 2025, 19:46 UTC

Achiziții, Fuziuni, Preluări

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 iul. 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 iul. 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 iul. 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 iul. 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 iul. 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 iul. 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11 iul. 2025, 16:42 UTC

Câștiguri

BASF Cuts Outlook on Global Economic Uncertainty

11 iul. 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 iul. 2025, 16:05 UTC

Câștiguri

BASF Will Publish Half-Year Results on July 30

11 iul. 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11 iul. 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 iul. 2025, 16:03 UTC

Câștiguri

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 iul. 2025, 16:02 UTC

Câștiguri

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 iul. 2025, 16:01 UTC

Câștiguri

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 iul. 2025, 16:00 UTC

Câștiguri

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 iul. 2025, 15:59 UTC

Câștiguri

BASF Cuts 2025 Earnings View

11 iul. 2025, 15:58 UTC

Câștiguri

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 iul. 2025, 15:57 UTC

Câștiguri

BASF 2Q EBIT Before Special Items EUR810M

11 iul. 2025, 15:54 UTC

Câștiguri

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 iul. 2025, 15:54 UTC

Câștiguri

BASF 2Q Sales Fell 2.1% on Year

11 iul. 2025, 15:53 UTC

Câștiguri

BASF 2Q Sales EUR15.77B

11 iul. 2025, 15:52 UTC

Câștiguri

BASF: This Was in Line With Consensus Estimates

11 iul. 2025, 15:52 UTC

Câștiguri

BASF 2Q Ebitda Before Special Items EUR1.77B

11 iul. 2025, 15:49 UTC

Câștiguri

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 iul. 2025, 15:41 UTC

Market Talk

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Comparație

Modificare preț

Crinetics Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

114.44% sus

Prognoză pe 12 luni

Medie 68.6 USD  114.44%

Maxim 97 USD

Minim 32 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCrinetics Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

11 ratings

9

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

30.39 / 33.46Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Neutral Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.